A Preventive Checklist for Men, Organized by What Actually Triggers Each Test

A well-built preventive checklist for men is short, and the useful trick is to file each test under the thing that should set it off: a blood pressure cuff at almost every visit, a birthday, a smoking history, or a number your clinician calculates. Sorted that way, the strongly supported list comes down to blood pressure measurement, colorectal cancer screening from age 45, lung cancer screening for eligible people who smoked, a cholesterol-anchored statin decision, and a single aneurysm ultrasound for older men who smoked. Prostate cancer screening sits apart on purpose, as a decision the guidelines want you to make with a clinician rather than a default to accept. Each item is here to inform a conversation, not to replace one.

Key points#

• Only a handful of screenings for men carry an A or B grade from the US Preventive Services Task Force (USPSTF); the rest are selective or not recommended.
• Sorting tests by their trigger (a routine visit, an age, a habit, or a risk score) makes the list easier to act on than a long menu of names.
• Prostate cancer screening is a graded shared decision for men 55 to 69 and is advised against for men 70 and older.
• A grade is a statement about the balance of benefit and harm, so knowing the grade matters as much as knowing the test.

What the grade is actually telling you#

The USPSTF sorts each service by how sure the evidence is that benefit outweighs harm. An A or B grade means the net benefit is at least moderate, so the service is generally recommended. A C grade means offer it selectively, guided by the individual rather than applied to everyone. A D grade means the harms win, and an I grade means the evidence is too thin to call. No screen is free: false positives, follow-up procedures, and overdiagnosis are real costs, which is exactly why the letter attached to a test carries as much information as the test's name.

The triggers, one at a time#

Triggered by almost any visit: blood pressure#

High blood pressure screening sits in the Task Force's strongest tier. For men 40 and older, or younger men at increased risk, checking the pressure periodically is reasonable, while younger men with prior normal readings and no added risk can be measured less often. The guidance also asks for confirmation of an elevated office reading with measurements taken outside the clinic before treatment begins, a safeguard against treating a number the appointment itself inflated.

Triggered by a birthday: colorectal screening and the aneurysm scan#

Two items are keyed almost entirely to age. Colorectal cancer screening starts at 45: the USPSTF recommends it for adults 45 to 75, with several acceptable methods from stool-based tests to colonoscopy, chosen by preference and access rather than mandate. From 76 to 85 the recommendation softens to a selective one, weighed against overall health and prior screening rather than age alone.

The second birthday-keyed item is a one-time abdominal aortic aneurysm ultrasound for men 65 to 75 who ever smoked. For men in that age band who never smoked, the scan is offered selectively rather than routinely. Both tests are easy to raise because the trigger is simply a number of years.

Triggered by a smoking history: lung screening#

Lung cancer screening turns on how much and how recently someone smoked. The 2021 USPSTF recommendation (grade B) covers annual low-dose CT for adults 50 to 80 with a 20 pack-year history who currently smoke or quit within the past 15 years. That update widened eligibility from the older 55-to-80, 30-pack-year threshold, pulling in more people at meaningful risk. Screening is meant to stop once a person has been smoke-free for 15 years, or develops a condition that would shorten life expectancy or make treatment hard to tolerate.

Triggered by a calculated risk: the statin conversation#

Cholesterol is not screened toward a single target number. The 2022 USPSTF guidance frames statins for primary prevention around estimated cardiovascular risk. For adults 40 to 75 with at least one risk factor (high cholesterol, diabetes, high blood pressure, or smoking) and an estimated 10-year risk of 10 percent or higher, the Task Force recommends a statin (grade B). When that estimated risk lands between 7.5 and 10 percent, the advice is to offer a statin selectively (grade C), because the expected gain is smaller. For adults 76 and older without established cardiovascular disease, the evidence was judged insufficient (grade I). The trigger here is not a lab value in isolation but a short calculation your clinician can run in the room.

Prostate cancer: built to be a conversation#

Prostate screening is the item where the framing does the most work. The USPSTF gives PSA-based screening for men 55 to 69 a grade C, meaning the choice to screen should be individual, made after weighing benefits and harms with a clinician. The Task Force describes a small possible reduction in prostate cancer deaths set against real harms: false positives, biopsies, overdiagnosis of cancers that would never have caused symptoms, and treatment effects such as incontinence and erectile dysfunction. For men 70 and older, the grade is D, against routine PSA-based screening, because the expected harms outweigh the benefit in that group. A grade C is not a verdict that screening is wrong; it signals that a well-informed man could reasonably choose either way.

Why testosterone testing is not on the list#

Low testosterone checks are sometimes sold as preventive upkeep, so it helps to separate a labeling change from a clinical recommendation. In February 2025 the FDA issued class-wide labeling changes for testosterone products, removing boxed-warning language about cardiovascular risk after the TRAVERSE trial found no rise in major adverse cardiovascular events among men treated for hypogonadism. The same update added a class-wide warning about increased blood pressure and kept a limitation-of-use note that these products are not established for age-related, as opposed to medically diagnosed, low testosterone. A label change describes what a product's documentation may legally say; it is not an endorsement, a prompt to start therapy, or a safety all-clear. Testosterone treats a diagnosed condition; it is not a screening item, and whether to test or treat is an individual decision made with a clinician who can weigh the diagnosis, the blood pressure signal, and the trial population.

Using this in a real appointment#

The value of the list is not its length but the fit between each test and your age, your history, and the strength of the evidence behind it. Walk in ready to check your blood pressure, confirm you are current on colorectal screening if you are 45 or older, ask about lung CT if your smoking history qualifies, run the cardiovascular risk number before deciding on a statin, and raise the aneurysm scan if you are an older man who smoked. Save the prostate question for an actual back-and-forth rather than a reflex yes or no. Framed as a set of shared decisions, a short visit turns into something you can genuinely steer.